InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

XENE Clue Score32
British Columbia, Canada Fiscal year ends December CIK 0001582313 Results filed 6 Aug 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

64
Insider
Date
Role
Action
Shares
Price
Amount
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
65,000
$62.06
$4.03M
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
61,652
$60.08
$3.70M
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
43,348
$59.26
$2.57M
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
2,449
$61.26
$150.03K
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
10,072
$60.47
$609.05K
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
12,479
$59.50
$742.50K
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
21,515
$60.49
$1.30M
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
31,694
$59.88
$1.90M
Ian Mortimer
9 Mar 2026
President & CEO
Sold after exercise
21,791
$58.81
$1.28M
Ian Mortimer
2 Jan 2026
President & CEO
Sold after exercise
2,062
$44.93
$92.65K
Ian Mortimer
2 Jan 2026
President & CEO
Sold after exercise
37,938
$44.40
$1.68M
Ian Mortimer
1 Oct 2025
President, CEO & Interim CFO
Sold after exercise
25,000
$40.16
$1.00M
Ian Mortimer
27 Jan 2025
President & CEO
Sold after exercise
1,149
$41.07
$47.19K
Ian Mortimer
27 Jan 2025
President & CEO
Sold after exercise
15,166
$40.46
$613.62K
Ian Mortimer
24 Jan 2025
President & CEO
Sold after exercise
22,468
$40.20
$903.21K
Ian Mortimer
23 Jan 2025
President & CEO
Sold after exercise
16,217
$40.08
$649.98K
Sherry Aulin
18 Dec 2024
Chief Financial Officer
Sold after exercise
11,510
$41.19
$474.10K
Sherry Aulin
18 Dec 2024
Chief Financial Officer
Sold after exercise
7,199
$41.23
$296.81K
Gary Patou
22 Nov 2024
Director
Sold after exercise
2,040
$41.05
$83.74K
Gary Patou
22 Nov 2024
Director
Sold after exercise
2,851
$41.11
$117.20K
Elizabeth A. Garofalo
8 Mar 2024
Director
Sold after exercise
2,092
$45.69
$95.58K
Sherrington Robin
7 Mar 2024
EVP, Strategy & Innovation
Sold after exercise
6,118
$46.30
$283.26K
Sherrington Robin
7 Mar 2024
EVP, Strategy & Innovation
Sold after exercise
1,019
$46.15
$47.03K
Gary Patou
13 Dec 2023
Director
Sold after exercise indirect
7,598
$41.05
$311.90K
Gary Patou
13 Dec 2023
Director
Sold after exercise
3,977
$39.84
$158.44K
Gary Patou
13 Dec 2023
Director
Sold after exercise
2,303
$39.10
$90.05K
Gary Patou
13 Dec 2023
Director
Sold after exercise
5,100
$38.94
$198.59K
Simon N. Pimstone
1 Jun 2023
Director
Sold after exercise
24,255
$38.78
$940.61K
Simon N. Pimstone
1 Jun 2023
Director
Sold after exercise
7,458
$38.97
$290.64K
Simon N. Pimstone
31 May 2023
Director
Sold after exercise
26,856
$38.69
$1.04M
Simon N. Pimstone
31 May 2023
Director
Sold after exercise
23,670
$38.81
$918.63K
Simon N. Pimstone
31 May 2023
Director
Sold after exercise
12,000
$38.53
$462.36K
Ian Mortimer
24 May 2023
President & CEO
Sold after exercise
1,407
$41.49
$58.38K
Ian Mortimer
24 May 2023
President & CEO
Sold after exercise
13,179
$41.37
$545.22K
Ian Mortimer
24 May 2023
President & CEO
Sold after exercise
17,069
$41.44
$707.34K
Simon N. Pimstone
7 Mar 2023
Director
Sold after exercise
8,242
$36.94
$304.46K
Simon N. Pimstone
7 Mar 2023
Director
Sold after exercise
10,990
$37.01
$406.74K
Gary Patou
25 Nov 2022
Director
Sold after exercise
1,937
$34.79
$67.39K
Sherry Aulin
2 Sep 2022
Chief Financial Officer
Sold after exercise
15,355
$39.57
$607.60K
Sherrington Robin
1 Sep 2022
EVP, Strategy & Innovation
Sold after exercise
8,776
$38.80
$340.51K
Sherrington Robin
1 Sep 2022
EVP, Strategy & Innovation
Sold after exercise
35,103
$38.03
$1.33M
Sherrington Robin
31 Aug 2022
EVP, Strategy & Innovation
Sold after exercise
21,352
$38.57
$823.55K
James R. Empfield
12 Aug 2022
EVP, Drug Discovery
Sold after exercise
21,875
$38.68
$846.13K
James R. Empfield
12 Aug 2022
EVP, Drug Discovery
Sold after exercise
35,868
$38.08
$1.37M
James R. Empfield
7 Mar 2022
EVP, Drug Discovery
Sold after exercise
31,048
$30.54
$948.21K
James R. Empfield
7 Mar 2022
EVP, Drug Discovery
Sold after exercise
1,805
$30.62
$55.27K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
2,500
$30.55
$76.38K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
7,500
$30.50
$228.75K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
2,500
$30.52
$76.30K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
4,516
$30.44
$137.47K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
4,516
$30.45
$137.51K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
4,517
$30.49
$137.72K
Simon N. Pimstone
7 Mar 2022
Director
Sold after exercise
5,037
$30.60
$154.13K
James R. Empfield
4 Mar 2022
EVP, Drug Discovery
Sold after exercise
18,315
$30.79
$563.92K
Sherrington Robin
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$30.23
$151.15K
Sherrington Robin
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$31.05
$155.25K
Sherrington Robin
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
5,000
$30.15
$150.75K
Sherrington Robin
4 Mar 2022
EVP, Strategy & Innovation
Sold after exercise
6,710
$30.56
$205.06K
Simon N. Pimstone
4 Mar 2022
Director
Sold after exercise
4,793
$30.56
$146.47K
Simon N. Pimstone
4 Mar 2022
Director
Sold after exercise
4,532
$30.66
$138.95K
Sherrington Robin
28 May 2021
EVP, Strategy & Innovation
Sold after exercise
2,912
$18.81
$54.77K
Sherrington Robin
28 May 2021
EVP, Strategy & Innovation
Sold after exercise
3,155
$18.81
$59.35K
Frank A Holler
27 May 2021
Director
Sold after exercise
8,485
$18.68
$158.50K
Frank A Holler
27 May 2021
Director
Sold after exercise
2,579
$18.69
$48.20K
Show all 219 transactions →

What was left out

Form 4 filings counted 258
Amendments (4/A) skipped 3
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 14
Sales straight out of an exercise 64
Sales at will 33
Transactions with no price 0
Shares from compensation/vesting 4,426,192
Sales filed before the plan box existed 23
History held since 6 Nov 2014